Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
Int J Mol Med · 2015
Last updated 2026-05-28In lab tests, high blood sugar harmed kidney cells and increased cell death in both human kidney cells and diabetic rats. The diabetes drug liraglutide reduced these harmful effects, while blocking its receptor increased them, suggesting liraglutide may protect kidneys from high blood sugar damage.
AI summary of the abstract below.
| Journal | Int J Mol Med, 2015 |
|---|---|
| Citations | 66 |
| Relative citation ratio | 2.44 |
| NIH percentile | 79 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
Tubular atrophy and dysfunction is a critical process underlying diabetic nephropathy (DN). Understanding the mechanisms underlying renal tubular epithelial cell survival is important for the prevention of kidney failure associated with glucotoxicity. Autophagy is a cellular pathway involved in protein and organelle degradation. It is associated with many types of cellular homeostasis and human diseases. To date, little is known of the association between high concentrations of glucose and autophagy in renal tubular cells. In the present study, we investigated high glucose-induced toxicity in renal tubular epithelial cells by means of several complementary assays, including cell viability, cell death assays and changes in ultrastructure in an immortalized human kidney cell line, HK-2 cells. The extent of apoptosis was significantly increased in the HK-2 cells following treatment with high levels of glucose. In addition, in in vivo experiments using diabetic rats, high glucose exerted harmful effects on the tissue structure of the kidneys in the diabetic rats. Chronic exposure of the HK-2 cells and tubular epithelial cells of nephritic rats to high levels of glucose induced autophagy. Liraglutide inhibited these effects; however, treatment witht a glucagon-like peptide-1 receptor (GLP‑1R) antagonist enhanced these effects. Our results also indicated that the exposure of the renal tubular epithelial cells to high glucose concentrations in vitro led to the downregulation of GLP-1R expression. Liraglutide reversed this effect, while the GLP-1R antagonist promoted it, promoting autophagy, suggesting that liraglutide exerts a renoprotective effect in the presence of high glucose, at least in part, by inhibiting autophagy and increasing GLP-1R expression in the HK-2 cells and kidneys of diabetic rats.
Verbatim abstract via PubMed 25573030 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.